Royalty Pharma plc - Ordinary Shares - Class A

NASDAQ:RPRX  
36.36
-0.34 (-0.93%)
7:00:07 PM EDT: $36.75 +0.39 (+1.07%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)15.57B
Current PE9.35
Forward PE 8.12
2yr Forward PE 7.2
See more stats
Estimates Current Quarter
Revenue$735.01 Million
Adjusted EPS$1.04
See more estimates
10-Day MA$36.33
50-Day MA$36.24
200-Day MA$32.22
See more pivots

Royalty Pharma plc - Ordinary Shares - Class A Stock, NASDAQ:RPRX

110 East 59th Street, 33rd floor, New York, New York 10022
United States of America
Phone: +1.212.883.0200
Number of Employees: 99

Description

Royalty Pharma Plc engages in the provision of drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio includes royalties, including AbbVie and J&J�s Imbruvica, Astellas and Pfizer�s Xtandi, Biogen�s Tysabri, Gilead�s HIV franchise, Merck�s Januvia, Novartis� Promacta, Vertex�s Kalydeco, Orkambi, Symdeko and Trikafta, and five development-stage product candidates. The company was founded by Pablo Gerardo Legorreta and Rory B. Riggs in 1996 and is headquartered in New York, NY.